Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.

@article{Siccardi2013PredictionOD,
  title={Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.},
  author={Marco Siccardi and Catia Marzolini and Kay Seden and Lisa Almond and Anna Kirov and Saye Khoo and Andrew Owen and David Back},
  journal={Clinical pharmacokinetics},
  year={2013},
  volume={52 7},
  pages={583-92}
}
BACKGROUND AND OBJECTIVE The rate of depression in patients with HIV is higher than in the general population. The use of antidepressants can have a beneficial effect, improving antiretroviral therapy adherence and consequently their efficacy and safety. Efavirenz and protease inhibitor boosted with ritonavir are major components of the antiretroviral therapy and are inducers and/or inhibitors of several cytochrome P450 (CYP) isoforms. Although antidepressants are prescribed to a significant… CONTINUE READING